Views
4 years ago

14 - A Diaz - Septiembre de 2011

  • Text
  • Diaz
  • Receptores
  • Betabloqueantes
  • Dosis
  • Riesgo
  • Arterial
  • Tradicionales
  • Tratamiento
  • Efectos
  • Pacientes
Rol actual de los betabloqueantes en el tratamiento de la hipertensión arterial

hemodynamics, and

hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987;10(suppl 11):S130-6. - Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol 1990;38(suppl 2):S96-S100. - Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201–207. - Fagard RH, Celis H, Thijs L, Wouters S. Regression of Left Ventricular Mass by Antihypertensive Treatment A Meta-Analysis of Randomized Comparative Studies. Hypertension. 2009;54: 1084-109. - Fassbinder W, Quarder O, Waltz A.. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract 1999;53(7):519-22. - Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L.Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14(1):27-31. - Fountoulaki K, Dimopoulos V, Giannakoulis J, et al. Left ventricular mass and mechanics in mild-to moderate hypertension: Effect of nebivolol versus telmisartan. Am J Hypertens.2005;18:171-177. - Frishman W, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc Health and Risk Manag 2008:4(6) 1387–1400. - Frishman WH. Carvedilol. New Engl J Med 1998; 339(24): 1759-1765. - Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12. - Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160:2447–2452. - Ignarro LJ. Different pharmacological properties of two enantiomers in a unique b-blocker, nebivolol. Cardiovasc Ther 2008; 26:115–134 - Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-41. - Khan N, McAlister FA. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737-42.ç - Lindholm LH, Carlberg B, Samuelsson O. Should B-blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005; 366: 1545–53. - Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of Newer b-Blockers for the Management of Hypertension. J Clin Hypertens (Greenwich). 2009;11: 369–375. - Mazza A, Gil-Extremera B, Maldonato A, et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 2002; 11 :182188. - Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of b-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706–2715. - Messerli FH, Bangalore S, Yao SS, Steinberg JS. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager. J Intern Med 2009; 266: 232–241. - Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?: a systematic review. JAMA 1998; 279:1903-7. - Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994; 26:335-46. - Münzel T, Gori T. Nebivolol. The Somewhat- Different -Adrenergic Receptor Blocker. J Am Coll Cardiol 2009;54:1491–9. - Panjrath GS, Messerli FH. B-Blockers for Primary Prevention in Hypertension: Era Bygone?. Prog Cardiovasc Dis 2006;, 49 (2): 76-87. - Pedersen M, Cockroft JR. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?. Curr Opin Cardiol 2009; 24:325–332. - Prichard BN, Gillam PM. Use of propranolol (Inderal) in treatment of hypertension. BMJ 1964; 5411:725-7. - Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agentsa systematic review and metaanalysis. JAMA 1997; 277:739-45. - Ram CV. Beta-blockers in hypertension. Am J Cardiol. 2010 Dec 15;106(12):1819-25. Epub 2010 Nov 2. - Reiter MJ. Cardiovascular Drug Class Specificity: B-Blockers. Progr Cardiovasc Dis 2004; 47 (1): 11-33. - Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist. J Hypertens 1996;14:1247–1255. - Sica DA, Black HR. Pharmacologic considerations in the positioning of b-blockers in antihypertensive therapy. Curr Hypertens Rep 2008; 10: 330–335. - Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298:1147-52. - Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health and Risk Manag 2008:4(1) 23–30. - Tsalta D, Anastasakis E, Papadogiannis DE. Beta-Blockers In The Treatment Of Hypertension: Latest Data And Opinions. Hellenic J Cardiol 2008; 48: 37-47. - Van Nueten L, Schelling A, Vertommen C, et al. Nebivolol vs enalapril in the treatment of essential hypertension: A double-blind randomized trial. J Hum Hypertens. 1997;11: 813- 819. - Weber K, Bohmeke T, van der DR, Taylor SH. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996;10:113-7. - Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988;35(suppl 6):118-34). - Williams B. b-blockers and the treatment of hypertension. J Hypertens 2007; 25:1351–1353. 14 | Editorial Sciens

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015